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Objective: It is generally assumed that hepatic inﬂammation in obesity is linked to the pathogenesis of
insulin resistance. Several recent studies have shed doubt on this view, which questions the causality of
this association. This study focuses on Kupffer cell-mediated hepatic inﬂammation as a possible driver of
insulin resistance in the absence and presence of obesity.
Methods: We used male mice deﬁcient for the low-density lipoprotein receptor (Ldlr/) and susceptible
to cholesterol-induced hepatic inﬂammation. Whole body and hepatic insulin resistance was measured
in mice fed 4 diets for 2 and 15 weeks, i.e., chow, high-fat (HF), HF-cholesterol (HFC; 0.2% cholesterol)
and HF without cholesterol (HFnC). Biochemical parameters in plasma and liver were measured and
inﬂammation was determined using immunohistochemistry and RT-PCR.
Results: At 2 weeks, we did not ﬁnd signiﬁcant metabolic effects in either diet group, except for the mice
fed a HFC diet which showed pronounced hepatic inﬂammation (p < 0.05) but normal insulin sensitivity.
At 15 weeks, a signiﬁcant increase in insulin levels, HOMA-IR, and hepatic insulin resistance was
observed in mice fed a HFC, HFnC, and HF diet compared to chow-fed mice (p < 0.05). Regardless of the
level of hepatic inﬂammation (HFC > HF, HFnC; p < 0.05) insulin resistance in mice fed HFC was no worse
compared to mice on a HFnC and HF diet.
Conclusion: These data show that cholesterol-induced hepatic inﬂammation does not contribute to the
development of insulin resistance in male Ldlr/ mice. This study suggests that Kupffer cell-driven
hepatic inﬂammation is a consequence, not a cause, of metabolic dysfunction in obesity.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Chronic inﬂammation, particularly when it occurs in metaboli-
cally important organs such as the liver and adipose tissue, is
considered to play a crucial role in the etiology of many metabolic
diseases, including type 2 diabetes, non-alcoholic fatty liver disease
(NAFLD) and cardiovascular disease [1,2]. As in adipose tissue,
obesity leads to an increase in pro-inﬂammatory gene expression in
the liver [3]. Pro-inﬂammatory pathways in Kupffer cells are acti-
vated in obesity and the production of inﬂammatory cytokines, University Medical Center
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nd Ltd. All rights reserved.secreted by these liver macrophages is linked to disruption of he-
patic insulin signaling and reduced insulin sensitivity in mice [2e
4]. For instance, LIKK mice with hepatocyte speciﬁc expression of
the IkB kinase b (IKKb), an upstream kinase that activates NF-kB, a
master regulator of inﬂammation, exhibit profound hepatic insulin
resistance with moderate systemic insulin resistance [3]. In line
with this, mice lacking IKKb in hepatocytes retain liver insulin
sensitivity in response to high-fat feeding, obesity or aging [5].
Although these and many other studies suggest that insulin resis-
tance is causally linked to hepatic inﬂammation [3,5,6], recent
studies show a disconnection between insulin resistance and he-
patic inﬂammation [7e11]. Moreover, obesity is a confounding
factor in most studies making it difﬁcult to dissect the role of he-
patic inﬂammation in the development of insulin resistance.
As Kupffer cells have been studied less extensively than adipose
tissue macrophages in the context of obesity and insulin resistance
A. Funke et al./ Atherosclerosis 232 (2014) 390e396 391[12] and Kupffer cell depletion studies have shown controversial
ﬁndings [8,13e15], we aimed to study the role of Kupffer cell-driven
hepatic inﬂammation in the development of insulin resistance in
the onset and presence of obesity. We used mice deﬁcient for the
low-density lipoprotein receptor (Ldlr/) [16], a humanizedmouse
model exhibiting many features of the metabolic syndrome when
fed a western style or diabetogenic diet, including obesity, insulin
resistance, dyslipidemia, inﬂammation and atherosclerosis [17,18].
When triggered with low levels of cholesterol (0.15e0.2%), Ldlr/
mice also displaymany features of humanNAFLD, including Kupffer
cell-driven hepatic inﬂammation [19e21]. This is in contrast to
C57BL/6 mice that develop hepatic steatosis and insulin resistance
without hepatic inﬂammation and further progression toward non-
alcoholic steatohepatitis [22]. Importantly, we have previously
shown that dietary cholesterol can provoke hepatic inﬂammation
within 7 days, in the absence of obesity [21], thereby serving as an
attractive model to unravel the role of Kupffer cell-driven hepatic
inﬂammation in the development of insulin resistance.2. Materials and methods
2.1. Mice and diet intervention
All procedures were performed with approval of the University
of Groningen Ethical Committee for Animal Experiments, which
adheres to the principles and guidelines established by the Euro-
pean Convention for the Protection of Laboratory Animals. Exper-
iments were carried out on male Ldlr/ mice (Jackson Laboratory,
Bar Harbor, USA, ME), housed individually in a temperature- and
light-controlled facility with ad libitum access to food and water.
At the age of 8e10 weeks, mice were divided into 4 groups of 6e
8 mice: (1) mice fed chow diet (2181, RMH-B, Hope Farms, Woer-
den, the Netherlands); (2) mice fed a high-fat-diet containing 36%
(w/w) fat from lard and 0.03% (w/w) cholesterol (HF; diet 4031.45,
Abdiets, Woerden, the Netherlands.); (3) mice fed HF-diet con-
taining 21% milk butter and 0.2% cholesterol (HFC; diet 0035, Sci-
entiﬁc Animal Food and Engineering, Villemoisson-sur-orge,
France); and (4) mice fed HF-diet containing 21% milk butter and
0.05% residual cholesterol derived from the butter component
(HFnC; diet 0136, Scientiﬁc Animal Food and Engineering,
Villemoisson-sur-orge, France). Mice were kept on these diets for 2
and 15 weeks and experiments were carried out simultaneously
using diets from the same batch number. After 2 and 15 weeks
animals were killed for the collection of blood, liver and muscle
samples.2.2. Dual-energy X-ray absorptiometry (DEXA) scan analysis
Fat and lean mass was determined in the same mice at 2 and 15
weeks following dietary intervention using Dual-Energy X-ray
Absorptiometry (p-DEXA, Norland Stratec Medizintechnik GmbH,
Birkenfeld, Germany). Mice were scanned under fed conditions
while anesthesized using isoﬂurane and data was analyzed ac-
cording to the manufacturer’s instructions.2.3. Oral glucose tolerance test
Mice were fasted for 9 h and a glucose bolus (2 g/kg of 20%
glucose solution) was given by oral gavage. Glucose levels were
measured with an OneTouch Ultra glucometer (Lifescan Benelux,
Beerse, Belgium) before and 15, 30, 60, 90, and 120 min after the
gavage.2.4. Insulin signaling studies in vivo
The mice were fasted overnight and subjected to an intraperi-
toneal injection with saline or human recombinant insulin (0.75 U/
kg body weight, Actrapid, Novo Nordisk Canada inc., Ontario,
Canada) 15 min before killing. Tissues were isolated and snap-
frozen in liquid nitrogen.
2.5. RT-PCR
Total RNAwas isolated from the liver with TRIzol reagent (Sigma
Aldrich, Zwijndrecht, the Netherlands) and total RNA (1 mg) from
each individual mouse was converted into cDNA with Quantitect
Reverse Transcription kit (QIAGEN, Venlo, the Netherlands).
Real time PCR (RT-PCR) was performed using a 7900HT system
(Applied Biosystems, Warrington, UK) and values were corrected
using the housekeeping gene Cyclophillin A (Ppia). The following
primers were used: F4/80 forward TGTGTCGTGCTGTTCAGAACC,
reverse AGGAATCCCGCAATGATGG; Clec4f forward TGAGTGGAA-
TAAAGAGCCTCCC, reverse TCATAGTCCCTAAGCCTCTGGA; Mcp-1
forward GCTGGAGAGCTACAAGAGGATCA, reverse ACA-
GACCTCTCTCTTGAGCTTGGT; Cmklr1, forward AACAGCCACTACCA-
GAACAAC, reverse CGTGACTGGAAATACCTTCTC; Tnf-a, forward
CATCTTCTCAAAATTCGAGTGACAA, reverse TGGGAGTAGA-
CAAGGTACAACCC and Il-1b, forward TGCAGCTGGAGAGTGTGG,
reverse TGCTTGTGAGGTGCTGATG; Ppia forward TTCCTCCTTTCA-
CAGAATTATTCCA, reverse CCGCCAGTGCCATTATGG.
2.6. Immunoblot analysis
Tissues were homogenized in ice-cold buffer (liver: NaCl
150 mM, TriseHCl pH 7.5 50 mM, EDTA 5 mM, Pyrophophate
30 mM, NaF 50 mM, Triton X-100, PMSF 100 mM, phosphatase
inhibitor cocktails; skeletal muscle: as shown previously [23]).
Equal amounts of protein were separated by SDS-PAGE, and
transferred to Polyvinylidene Diﬂuoride membranes (GE Health-
care Life Sciences, Diegem, Belgium). Phosphorylated and total AKT
antibodies were purchased from Cell Signaling Technology (Leiden,
the Netherlands). Immune-complexes were visualized by chem-
iluminescence (GE Healthcare Life Sciences, Diegem, Belgium) and
quantiﬁed by densitometry (imageJ software, National Institute of
Health).
2.7. Statistical analysis
Data are expressed as means  SEM for the indicated number of
observations. Statistical signiﬁcance between groups was deter-
mined using a two-tailed ManneWhitney U test. Multiple com-
parison analysis was performed using two-way ANOVA with a
Bonferroni post hoc test to correct for multiple testing. Two-way
ANOVA for repeated measurements was used to test for compari-
sons in body weight and fat mass between the 2- and 15-week time
points. Values of p < 0.05 were considered statistically signiﬁcant.
The software used for the analysis was GraphPad Prism (version
5.00 for Windows, GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Dietary cholesterol triggers Kupffer cell activation
To conﬁrm Kupffer cell involvement following cholesterol sup-
plementation to the diet, immunostaining against Cd68 and Cd11b
was performed in liver sections of Ldlr/ mice fed chow, HF, HFC
and HFnC diet for 2 and 15 weeks. Indeed, macrophage size and
number (Fig. 1A) was signiﬁcantly increased in the livers of 2-week
Fig. 1. Dietary cholesterol triggers Kupffer Cell Activation. (A) Representative pictures of Cd68 staining and morphometric analysis of Cd68 stained liver sections from Ldlr/ mice
fed a chow, HF, HFC or HFnC diet for 2 and 15 weeks. Original magniﬁcation 200. Kupffer cells are indicated with arrows. (B) RT-PCR analysis of hepatic F4/80 and Clec4f and (C)
Mcp-1 and Cmklr1 mRNA expression. Data is expressed as fold induction vs 2-week chow-fed Ldlr/ mice. Data are expressed as means  SEM, n ¼ 6 in each group. * p < 0.05 vs
chow-fed mice (ManneWhitney U Test); # p < 0.05 2- vs 15-week diet period (two-way ANOVA).
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(p < 0.05). Consistent with this, the number of Cd11bþ-
macrophages was signiﬁcantly increased in Ldlr/ mice after 2
weeks of HFC feeding when compared to mice fed chow, HF and
HFnC diet (Supplemental Fig. 1; p < 0.05). In addition, 2 weeks of
HFC feeding resulted in an increase in the expression levels of the
speciﬁc Kupffer cell markers F4/80 (Fig. 1B; p < 0.05 vs chow, HF,
HFnC) and Clec4f (C-type lectin domain family 4, member f; Fig. 1B;
p < 0.05 vs chow, HF, HFnC). Consistent with this, HFC feeding
resulted in a concomitant increase in the expression level of
monocyte chemotactic protein-1 (Mcp-1, Fig. 1C) and chemokine-
like receptor 1 (Cmklr1, Fig. 1C; p < 0.05 vs chow, HF, HFnC,
ANOVA), genes known to be involved in monocyte/macrophage
migration and inﬁltration [12,24].
Similar to 2 weeks of HFC feeding, feeding mice a HFC diet for 15
weeks resulted in amarked increase in Kupffer cell size and number
(Fig.1A), andCd11b cell count (Supplemental Fig.1)when compared
tomice fed chow, HF and HFnC diet for 15weeks (p< 0.05, ANOVA).
In addition, Kupffer cell number was signiﬁcantly enhanced in liver
sections of Ldlr/ mice subjected to 15 weeks of HFC feeding
compared to 2weeks of HFC feeding (Fig.1A). However, the number
of Cd11bþ-macrophages in liver sections of Ldlr/ mice fed a HFC
diet did not change overtime (Supplemental Fig. 1). In addition,
hepatic F4/80 and Clec4f expression levels were not signiﬁcantly
increased in 15-week HFC-fed mice compared to 2-weeks HFC-fed
mice (Fig. 1B; ANOVA). Furthermore, hepatic Mcp-1 and Cmklr1
levelswere increased in 15-weekHFC-fedmice compared to2-week
HFC-fed mice (Fig. 1C). 15 weeks of high-fat feeding with low levelsof cholesterol (HF, HFnC) also led to a signiﬁcant increase in F4/80,
Clec4f,Mcp-1 and Cmklr1 expression compared to chow-fed Ldlr/
mice (Fig. 1B, C). However, this increase was relatively small
compared to mice fed a HFC diet for 15 weeks (F4/80, HF vs HFC
p<0.01;HFnCvsHFC p<0.2468; Clec4f, HF vsHFC p<0.01;HFnC vs
HFC p < 0.1320; Mcp-1, HF vs HFC p < 0.01; HFnC vs HFC p < 0.01;
Cmklr, HF vs HFC p < 0.01; HFnC vs HFC p < 0.01).
3.2. Hepatic inﬂammation is sustained after long-term HFC feeding
in Ldlr/ mice
To assess whether enhanced Kupffer cell activation translates
into increased hepatic inﬂammation, we performed gene expres-
sion analysis for the inﬂammatory mediators Tnf-a, and Il-1b in the
livers of Ldlr/ mice at both time points. The expression of these
genes was signiﬁcantly increased in Ldlr/mice fed a HFC diet for 2
weeks when compared to mice fed chow, HF and HFnC diet (Fig. 2A,
B, p < 0.05). Mice fed a HF diet containing 0.03% cholesterol also
showed a signiﬁcant up regulation of these genes above chow
levels (Fig. 2A, B), but this was only modest compared to HFC-fed
mice (Tnf-a, HF vs HFC p < 0.01; Il-1b, HF vs HFC p < 0.01). More-
over, hepatic inﬂammation was absent in the mice fed a HFnC diet
for 2 weeks, highlighting the speciﬁcity of our cholesterol supple-
mentation model in inducing hepatic inﬂammation.
In addition, 15 weeks of HFC feeding led to a similar signiﬁ-
cant increase in inﬂammatory gene expression compared to 2
weeks of HFC feeding (Fig. 2A, B). However, it did not further
increase the levels of these genes above the 2-week time point.
Fig. 2. Kupffer cell-mediated hepatic inﬂammation is sustained after long-term HFC
feeding in Ldlr/ mice. (A) RT-PCR analysis of Tnf-a and (B) Il-1b mRNA expression in
livers from Ldlr/ mice fed a chow, HF, HFC or HFnC diet for 2 and 15 weeks. Data is
expressed as fold induction vs 2-week chow-fed Ldlr/ mice. Data are expressed as
means  SEM, n ¼ 6 in each group. * p < 0.05 vs chow-fed mice (ManneWhitney U
Test); # p < 0.05 2- vs 15-week diet period (two-way ANOVA).
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inﬂammation, albeit less pronounced compared to HFC feeding
(Tnf-a, HF vs HFC p < 0.01; Il-1b, HF vs HFC p < 0.05). Similar
results were obtained for 15 weeks of HFnC feeding in mice,
although Il-1b did not reach statistical signiﬁcance (Tnf-a, HFnC
vs HFC p < 0.05).Fig. 3. Dietary cholesterol does not lead to overt changes in adiposity in Ldlr/ mice.
(A) Body weight of Ldlr/ mice fed a chow, HF, HFC or HFnC diet for 2 (n ¼ 12 in each
group) and 15 weeks (n ¼ 12 in each group). (B) Fat mass was determined by DEXA
scan analysis (n ¼ 6 in each group). Data are expressed as means  SEM. * p < 0.05 vs
chow-fed mice (ManneWhitney U Test); # p < 0.05 2- vs 15-week diet period (two-
way ANOVA for repeated measurements).3.3. Dietary cholesterol does not lead to overt changes in adiposity
in Ldlr/ mice
As body weight adversely affects insulin sensitivity, Ldlr/mice
were subjected to DEXA scan analysis to determine fat mass at the
end of the 2- and 15-week diet period. After 2 weeks, body weight
(Fig. 3A) and fat mass (Fig. 3B) did not differ signiﬁcantly amongst
the 4 diet groups. At the end of the 15-week diet period body
weight (Fig. 3A) and fat mass (Fig. 3B) were signiﬁcantly increased
in mice fed a HFC and HF diet compared to the 15-week chow
controls and the respective 2-week time points (Fig. 3A, B). How-
ever, body weight was lower in 15-week HFC-fedmice compared to
HF-fedmice (p< 0.05), although fat mass did not differ signiﬁcantly
between these groups (Fig. 3B; HFC vs HF p ¼ 0.20). In addition,
body weight was signiﬁcantly lower in HFnC-fed mice compared to
both HFC- and HF-fed mice (Fig. 3A; HFnC vs HFC p< 0.05; HFnC vs
HF p < 0.01). Plasma and liver cholesterol levels were increased in
Ldlr/ mice fed a HFC, HF and HFnC diet compared to chow-fed
mice at either time point (Supplemental Tables 1, 2). In addition,
plasma and liver cholesterol levels were markedly increased in
HFC-fed mice compared to mice fed HFnC and HF diet. Further-
more, we observed higher plasma and hepatic TC levels in HFnC-fed mice compared to HF-fed mice (Supplemental Tables 1, 2).
This may be due to the higher residual cholesterol component in
the HFnC diet (0.05%) compared to the HF diet (0.03%). Plasma
triglycerides (TG) were elevated in all mice following HF feeding at
2 and 15 weeks compared to chow controls and no differences were
observed betweenHFC-, HFnC- and HF-fedmice at both time points
(Supplemental Tables 1, 2). Furthermore, hepatic TG levels were
signiﬁcantly increased in mice fed a HFC, HF and HFnC diet
compared to chow-fed mice at the 2-week time point
(Supplemental Table 1) and did not differ at the 15-week time point
(Supplemental Table 2).
3.4. Hepatic inﬂammation does not induce insulin resistance in lean
Ldlr/ mice
To investigate whether hepatic inﬂammation may affect glucose
metabolism, we assessed glucose tolerance, plasma insulin levels,
and the calculated HOMA-IR index as markers of insulin resistance.
At 2 weeks, Ldlr/ mice fed a HFC diet did not exhibit elevated
fasted insulin levels compared to mice fed a HF and HFnC diet
(Fig. 4A) nor was their glucose tolerance negatively affected
(Fig. 4B). Consistent with this, HOMA-IR was not signiﬁcantly
increased in the mice fed a HFC diet (Fig. 4C) compared to chow,
HF-, or HFnC-fed mice, suggesting that cholesterol-induced hepatic
inﬂammation does not induce the development of systemic insulin
resistance. In addition, no differences were observed in phosphor-
ylation status of AKT in either skeletal muscle or liver (Fig. 4D) in
the Ldlr/ mice fed a HFC diet compared to chow-, HF-, or HFnC-
fed mice, suggesting that insulin signaling in these metabolically
active tissues was not impaired.
Fig. 4. Hepatic inﬂammation does not induce insulin resistance in lean Ldlr/mice. (A) Plasma insulin levels in Ldlr/mice fed a chow, HF, HFC or HFnC diet for 2 weeks (n ¼ 6 in
each group). (B) Blood glucose levels during an oral glucose tolerance test (n ¼ 6 in each group). (C) HOMA-IR as a surrogate marker of insulin resistance (n ¼ 6 in each group). (D)
Western blot analysis of phosphorylated and total AKT in skeletal muscle and liver after an insulin injection (n ¼ 8 in each group). * p < 0.05 vs chow-fed mice (ManneWhitney U
Test). Data are expressed as means  SEM.
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obese Ldlr/ mice
Although our data indicate that Kupffer cell-mediated hepatic
inﬂammation may not increase the susceptibility toward the
development of insulin resistance during the onset of obesity, it
may still aggravate insulin resistance in obese Ldlr/ mice. How-
ever, glucose tolerance was not affected in Ldlr/ mice fed either
HFC or HFnC diet, and was only impaired in mice fed the diabeto-
genic HF diet (Fig. 5A). In spite of this, fasted insulin levels (Fig. 5B)
and HOMA-IR (Fig. 5C) were all signiﬁcantly increased compared to
the chow controls but did not differ between the HFC-, HFnC-, and
HF-fed groups. Whereas, insulin signaling in skeletal muscle did
not seem to be impaired after 15 weeks of HFC-, HFnC- and HF-
feeding compared to chow-fed mice, hepatic insulin resistance
was observed in mice on a HFC diet but again was no worse
compared to mice on a HFnC and HF diet (Fig. 5D). This was indi-
cated by a similar reduction in insulin-stimulated AKT phosphor-
ylation in the livers of these mice (Fig. 5D).
4. Discussion
In this study, we have explored the role of hepatic inﬂammation
as a possible driver of insulin resistance in the onset and presence
of obesity. We show that Ldlr/ mice with pronounced hepatic
inﬂammation, induced by a 2-week HFC-diet, do not exhibit signs
of insulin resistance in comparison to mice fed a HFnC-diet (Fig. 4).
We also show that insulin resistance is not aggravated in obese
Ldlr/mice with sustained hepatic inﬂammation induced by a 15-
week HFC-diet (Fig. 5) compared to mice fed a HFnC-diet. More-
over, we did not ﬁnd any correlation between the level of hepatic
inﬂammation, insulin resistance and/or obesity in these mice
(Supplemental Table 3). Therefore, our data show that HFC-induced
hepatic inﬂammation per sé does not cause insulin resistance in
Ldlr/ mice.Although previous studies have elegantly shown that insulin
resistance is causally related to hepatic inﬂammation [3,5], our data
donot support theseﬁndings. The reason for this is unclear; however,
it may be related to the experimental model used to assess the cau-
sality of this association. In this study, we used a Kupffer cell-based
approach to drive hepatic inﬂammation, whereas hepatic inﬂam-
mation in LIKKmice [3] and IkbkbDhep mice [5] is hepatocyte-driven.
This raises the question whether hepatocyte-driven inﬂammation is
functionally different from Kupffer cell-driven inﬂammation and
whether or not there is a distinctive role in their control of insulin
resistance. Nonetheless, it should be noted that IkbkbDhepmice retain
liver insulin responsiveness in response to a high-fat diet, obesity and
aging, but continue to develop peripheral insulin resistance inmuscle
and fat [5]. By contrast, LIKK mice expressing constitutively active
(IKKb) in hepatocytes exhibit insulin resistance both locally in liver
and systemically [3]. Therefore, the possibility arises that a causal
relationship between hepatic inﬂammation and insulin resistance
mayonlyexist in the liver andnot systemically. In addition, deletionof
Ikbkb inmyeloid cellswas reported to lead to a global improvement in
insulin sensitivity in IkbkbDmye mice [5] but this effect may not be
attributed to Kupffer cells in the liver as the LysM promotor used to
generate these mice is not active in Kupffer cells [25]. However,
Kupffer cell depletion studies have shown conﬂicting results, and
have both been associated with improvement [13e15] and deterio-
ration of hepatic insulin resistance [8], thereby questioning a role of
Kupffer cells in control of hepatic and global insulin sensitivity.
In this studywe have assessed parameters on two different scales,
i.e. inﬂammation and insulin resistance. On these two scales, changes
may not be in the same magnitude. Therefore, we cannot exclude
that the absence of insulin resistance at week 2 of HFC-feeding may
in fact reﬂect a temporal delay of onset of insulin resistance induced
by hepatic inﬂammation. Nevertheless, several other reports have
also raised doubts on the current concept that hepatic inﬂammation
causes insulin resistance inmice.Mice lacking the TNF receptors, p55
and p75, do not show improvement of insulin resistance despite
Fig. 5. Hepatic inﬂammation does not aggravate insulin resistance in obese Ldlr/ mice. (A) Blood glucose levels during an oral glucose tolerance test and AUC for the glucose
tolerance test in Ldlr/mice at 15 weeks on a chow, HF, HFC or HFnC diet (n ¼ 6 in each group). (B) Plasma insulin levels (n ¼ 6 in each group). (C) HOMA-IR (n ¼ 6 in each group).
(D) Representative western blot analysis of phosphorylated and total AKT in skeletal muscle and liver after an insulin injection (n ¼ 8 in each group). * p < 0.05 vs chow-fed mice
(ManneWhitney U Test). Data are expressed as means  SEM.
A. Funke et al./ Atherosclerosis 232 (2014) 390e396 395reduced levels of hepatic inﬂammation [11]. Consistent with this,
mice deﬁcient for MyD88, an adapter protein for TLR/IL-1 receptor
signaling, are more prone to develop metabolic disease in response
to HF feeding despite lower levels of inﬂammation [9]. Furthermore,
hepatic insulin resistance is not always associated with the presence
of inﬂammation in the liver as Liv-diacylglycerol O-acyltransferase 2
(DGAT2) mice fed a chow diet show hepatic insulin resistance in the
absence of liver inﬂammation [10]. In addition, we have recently
shown that hepatic inﬂammation is not associated with insulin
resistance in TNFR1 non-sheddable mice with a gain of function
mutation in the TNFR1 resulting in chronic low-grade inﬂammation
in the liver [7]. Moreover, mice with the non-shedding mutation fed
a chow diet for one year were not prone to developing insulin
resistance, nor did 12 weeks of HF feeding at the age of one year
accelerate the onset of insulin resistance in thesemice [7]. Therefore,
our data and the above-discussed studies all show, using different
experimental approaches (genetically engineered mouse models,
Kupffer cell depletion, and dietary intervention), a disconnection
between hepatic inﬂammation and the existence of insulin resis-
tance. A similar dissociation has also been observed between hepatic
steatosis and insulin resistance in various genetically andpharmacologically manipulated mouse models [26e29] and war-
rants further study.
Our data suggest that other obesity-associated factors may be
responsible for the development of insulin resistance in our mice.
Obesity is known to promote insulin resistance and adiposity was
signiﬁcantly increased in all HF diet groups following 15weeks ofHF
feeding (Fig. 3) whereas inﬂammatory gene expression in the liver
did not increase above the 2-week time point (Fig. 2). Moreover,
systemic and hepatic insulin resistance only became apparent with
increasing adiposity in Ldlr/ mice suggesting that signals origi-
nating from the adipose tissue rather than the liver may have
interfered with proper insulin signaling in the Ldlr/ mice. This is
consistentwith recent data showing that increased inﬂammation in
both liver and muscle only became apparent after establishment of
obesity [4]. Our studies cannot answer the question whether total
adiposity may be the driving force behind the development of in-
sulin resistance in our model or whether site-speciﬁc fat depots
(visceral or subcutaneousadipose tissue), a reduced capacity to store
excess nutrients, and/or an altered secretion of adipokines may be
involved. In addition, it has previously been shown that dietary
lipids and cholesterol (high-fat diet feeding) induce the inﬁltration
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secretion of inﬂammatory cytokines and chemokines by these
inﬁltrated macrophages [30e32]. Consequently this leads to beta
cell dysfunction and in impaired insulin secretion and hyperglyce-
mia [30e32]. As we observed a signiﬁcant increase in the insulin
levels following 15-weeks of dietary intervention in all HF-diet
groups compared to chow-fed feeding (Fig. 5B), our data may thus
conﬁrm a role for beta-cell involvement in the development of in-
sulin resistance in our study. Although cholesterolmaycontribute to
impaired beta cell function and glucose intolerance in Ldlr/mice
[33], HFC feeding did not aggravate the level of insulin resistance in
our study thereby excluding a role for cholesterol-driven beta-cell
impairment in the development of insulin resistance.
In summary, our results demonstrate that the level of Kupffer
cell-mediated hepatic inﬂammation is not directly correlated to the
development of insulin resistance in male Ldlr/ mice. Similar to
the dissociation between hepatic steatosis and insulin resistance,
we show dissociation between hepatic inﬂammation and the
development of insulin resistance in mice. Therefore, our data
provides evidence to question a possible role of Kupffer cell-driven
hepatic inﬂammation in insulin resistance in mice. However, in
order to exclude Kupffer cell-driven hepatic inﬂammation as a
cause of metabolic dysfunction in obesity, Kupffer cell depletion
studies need to be performed.
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